SAGE Therapeutics (SAGE) Misses Q3 EPS by 36c, Reports $1.8B of Cash on Hand

SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($2.21), $0.36 worse than the analyst estimate of ($1.85). Revenue for the quarter came in at $1.44 million versus the consensus estimate of $1.96 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• WeTouch Technology forecasts 40% revenue growth for fiscal 2026
• BofA Securities Starts PhysicsWallah Ltd (PWL:IN) at Underperform